CSL (ASX:CSL) share price dips amid $10b acquisition rumours

The biotech giant’s share price finished in the red on Thursday.
The post CSL (ASX:CSL) share price dips amid $10b acquisition rumours appeared first on The Motley Fool Australia. –

Shares in global biotech giant CSL Limited (ASX: CSL) edged lower today and finished more than 1% in the red at $305.23.

CSL held the fort across the day, with intraday prices trading in a narrow spread of $307–$308 before a large set of trades sent its share price as low as $301.11.

Acquisition rumours?

Rumours are circulating that the Aussie biotech is set to buy Vifor Pharma, a Swiss-based company, in a deal that could see CSL fork out $10 billion.

According to reporting from The Australian, CSL might be heading to the capital markets to raise additional equity capital to the tune of $3 billion–$4 billion.

Both CSL and Vifor have been in a game of verbal ping-pong with talks of the acquisition first circulating back in March this year. If the deal goes through, it would mark the CSL’s first major acquisition in over 10 years.

It is understood that Bank of America and Goldman Sachs are to be involved with the transaction, and both banks will nab a hefty fee from CSL’s capital raise if it is successful.

Vifor states that it aims to be a leader in iron deficiency, nephrology and cardio-renal therapies, with a focus on chronic disease.

It recognised 1.7 billion Swiss Francs in revenue in 2020 and has a market cap of 6.75 billion Swiss Francs ($10.33 billion). For comparison, CSL’s market cap is $140.88 billion.

Vifor itself has been busy on the acquisition trail as well, recently confirming it bought 100% of cardio-renal biopharma company, Sanifit Therapeutics on 22 November.

Curiously, former CSL non-executive director, Abbas Hussain – who resigned from CSL’s board in June this year – was recently appointed as the new CEO of Vifor Pharma.

Hussain joined the company on 16 August and will hold tenure as Vifor’s top executive after serving on CSL’s board for 4 years.

Without further clarification from CSL itself, it is unwise to make any speculation on the matter. However, CSL is well capitalised with over $8.3 billion in net assets – of which $1.8 billion is in cash on the balance sheet.

CSL share price snapshot

The CSL share price has climbed almost 1% in the past 12 months and almost 8% this year to date.

In the past week, it has slipped almost 4% but is in the green by 2% in the past month.

The post CSL (ASX:CSL) share price dips amid $10b acquisition rumours appeared first on The Motley Fool Australia.

Should you invest $1,000 in CSL right now?

Before you consider CSL, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

The Starpharma (ASX: SPL) share price surges on Vietnam launch

Advisor reveals the 3 most popular ASX shares among his clients

The CSL (ASX:CSL) share price reached a new 52-week high last week. What’s next?

CSL (ASX:CSL) share price higher on US FDA flu vaccine news

CSL (ASX:CSL) share price struggles despite new government funding

The author has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!